Merit Medical Systems, Inc. (MMSI), a healthcare technology company, Tuesday said that it has acquired Biolife Delaware, L.L.C. for about $120 million in cash.
Through the acquisition, Biolife, a maker of hemostatic devices, has become the wholly-owned subsidiary of Merit.
The transaction is expected to be slightly dilutive to the company's full-year adjusted profitability given the partial-year contribution.
Additionally, the company has reiterated its full-year outlook.
"The acquisition provides effective, differentiated, hemostatic solutions for all percutaneous devices with a broad range of clinical applications including vascular closure and indwelling catheter bleeding complications. BioLife's StatSeal and WoundSeal products address an estimated $350 million global market opportunity, are clinically validated, and will enhance our ability to deliver comprehensive solutions to our customers," said Fred P. Lampropoulos, Merits Chairman and Chief Executive Officer.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.